(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 41.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Tg Therapeutics's revenue in 2025 is $329,004,000.On average, 4 Wall Street analysts forecast TGTX's revenue for 2025 to be $85,779,696,560, with the lowest TGTX revenue forecast at $84,750,570,153, and the highest TGTX revenue forecast at $87,880,986,713. On average, 4 Wall Street analysts forecast TGTX's revenue for 2026 to be $114,419,159,853, with the lowest TGTX revenue forecast at $102,044,040,460, and the highest TGTX revenue forecast at $122,577,876,730.
In 2027, TGTX is forecast to generate $146,438,467,778 in revenue, with the lowest revenue forecast at $128,797,871,500 and the highest revenue forecast at $164,264,407,335.